Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases

Molecular Nutrition and Food Research

Volumn 55, Issue 6, 2011, Pages 832-843

  Shimizu, Masahito ^a   Adachi, Seiji ^a   Masuda, Muneyuki ^b   Kozawa, Osamu ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYUSHU KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

Colorectal cancer; EGCG; Hepatocellular carcinoma; Lipid rafts; Receptor tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; CATECHIN; PLANT EXTRACT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANIMAL; CELL MEMBRANE; CHEMISTRY; CHEMOPROPHYLAXIS; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PHYTOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; TEA;

ANIMALS; ANTICARCINOGENIC AGENTS; CATECHIN; CHEMOPREVENTION; HUMANS; MEMBRANE MICRODOMAINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TEA;

EID: 79958073312     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201000622     Document Type: Review

References (107)

1. Yang, C. S., Maliakal, P., Meng, X., Inhibition of carcinogenesis by tea. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 25-54.
2. Yang, C. S., Wang, X., Lu, G., Picinich, S. C., Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat. Rev. Cancer 2009, 9, 429-439.
3. Shimizu, M., Weinstein, I. B., Modulation of signal transduction by tea catechins and related phytochemicals. Mutat. Res. 2005, 591, 147-160.
4. Shimizu, M., Shirakami, Y., Moriwaki, H., Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG. Int. J. Mol. Sci. 2008, 9, 1034-1049.
5. Khan, N., Afaq, F., Saleem, M., Ahmad, N. et al., Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res. 2006, 66, 2500-2505.
6. Okabe, S., Ochiai, Y., Aida, M., Park, K. et al., Mechanistic aspects of green tea as a cancer preventive: effect of components on human stomach cancer cell lines. Jpn. J. Cancer Res. 1999, 90, 733-739.
7. Schlessinger, J., Cell signaling by receptor tyrosine kinases. Cell 2000, 103, 211-225.
8. Lemmon, M. A., Schlessinger, J., Cell signaling by receptor tyrosine kinases. Cell 2010, 141, 1117-1134.
9. Hynes, N. E., Lane, H. A., ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341-354.
10. Pollak, M. N., Schernhammer, E. S., Hankinson, S. E., Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 2004, 4, 505-518.
11. Ellis, L. M., Hicklin, D. J., VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8, 579-591.
12. Shimizu, M., Fukutomi, Y., Ninomiya, M., Nagura, K. et al., Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol. Biomarkers Prev. 2008, 17, 3020-3025.
13. Shimizu, M., Shirakami, Y., Sakai, H., Adachi, S. et al., (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev. Res. 2008, 1, 298-304.
14. Shimizu, M., Sakai, H., Shirakami, Y., Yasuda, Y. et al., Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Prev. Res. 2011, 4, 396-403.
15. Shirakami, Y., Shimizu, M., Tsurumi, H., Hara, Y. et al., EGCG and Polyphenon E attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. Mol. Med. Rep. 2008, 1, 355-361.
16. Shirakami, Y., Shimizu, M., Adachi, S., Sakai, H. et al., (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci. 2009, 100, 1957-1962.
17. Shimizu, M., Shirakami, Y., Sakai, H., Yasuda, Y. et al., (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells. Chem. Biol. Interact. 2010, 185, 247-252.
18. Hou, Z., Sang, S., You, H., Lee, M. J. et al., Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res. 2005, 65, 8049-8056.
19. Han, C., Screening of anticarcinogenic ingredients in tea polyphenols. Cancer Lett. 1997, 114, 153-158.
20. Rodriguez, S. K., Guo, W., Liu, L., Band, M. A. et al., Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int. J. Cancer 2006, 118, 1635-1644.
21. Tachibana, H., Koga, K., Fujimura, Y., Yamada, K., A receptor for green tea polyphenol EGCG. Nat. Struct. Mol. Biol. 2004, 11, 380-381.
22. Umeda, D., Yano, S., Yamada, K., Tachibana, H., Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor. J. Biol. Chem. 2008, 283, 3050-3058.
23. Leone, M., Zhai, D., Sareth, S., Kitada, S. et al., Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res. 2003, 63, 8118-8121.
24. Chung, J. Y., Park, J. O., Phyu, H., Dong, Z., Yang, C. S., Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3, 3'-digallate. FASEB J. 2001, 15, 2022-2024.
25. Chung, J. Y., Huang, C., Meng, X., Dong, Z., Yang, C. S., Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res. 1999, 59, 4610-4617.
26. Coffey, R. J., Jr., Shipley, G. D., Moses, H. L., Production of transforming growth factors by human colon cancer lines. Cancer Res. 1986, 46, 1164-1169.
27. Markowitz, S. D., Molkentin, K., Gerbic, C., Jackson, J. et al., Growth stimulation by coexpression of transforming growth factor-alpha and epidermal growth factor-receptor in normal and adenomatous human colon epithelium. J. Clin. Invest. 1990, 86, 356-362.
28. Malecka-Panas, E., Kordek, R., Biernat, W., Tureaud, J. et al., Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. Hepatogastroenterology 1997, 44, 435-440.
29. Ito, Y., Takeda, T., Sakon, M., Tsujimoto, M. et al., Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br. J. Cancer 2001, 84, 1377-1383.
30. Hakam, A., Yeatman, T. J., Lu, L., Mora, L. et al., Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum. Pathol. 1999, 30, 1128-1133.
31. Scharf, J. G., Braulke, T., The role of the IGF axis in hepatocarcinogenesis. Horm. Metab. Res. 2003, 35, 685-693.
32. Huynh, H., Chow, P. K., Ooi, L. L., Soo, K. C., A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ. 2002, 13, 115-122.
33. Aishima, S., Basaki, Y., Oda, Y., Kuroda, Y. et al., High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. Cancer Sci. 2006, 97, 1182-1190.
34. Cascinu, S., Staccioli, M. P., Gasparini, G., Giordani, P. et al., Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin. Cancer Res. 2000, 6, 2803-2807.
35. Giatromanolaki, A., Koukourakis, M. I., Sivridis, E., Chlouverakis, G. et al., Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur. J. Clin. Invest. 2007, 37, 878-886.
36. Ng, I. O., Poon, R. T., Lee, J. M., Fan, S. T. et al., Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am. J. Clin. Pathol. 2001, 116, 838-845.
37. Dhar, D. K., Naora, H., Yamanoi, A., Ono, T. et al., Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res. 2002, 22, 379-386.
38. Liang, Y. C., Lin-shiau, S. Y., Chen, C. F., Lin, J. K., Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J. Cell Biochem. 1997, 67, 55-65.
39. Masuda, M., Suzui, M., Weinstein, I. B., Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin. Cancer Res. 2001, 7, 4220-4229.
40. Masuda, M., Suzui, M., Lim, J. T., Deguchi, A. et al., Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J. Exp. Ther. Oncol. 2002, 2, 350-359.
41. Masuda, M., Suzui, M., Lim, J. T., Weinstein, I. B., Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin. Cancer Res. 2003, 9, 3486-3491.
42. Shimizu, M., Deguchi, A., Lim, J. T., Moriwaki, H. et al., (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin. Cancer Res. 2005, 11, 2735-2746.
43. Shimizu, M., Deguchi, A., Joe, A. K., McKoy, J. F. et al., EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. J. Exp. Ther. Oncol. 2005, 5, 69-78.
44. Gupta, R. A., Dubois, R. N., Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 2001, 1, 11-21.
45. Zahorowska, B., Crowe, P. J., Yang, J. L., Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. J. Cancer Res. Clin. Oncol. 2009, 135, 1137-1148.
46. Zhang, X., Zhang, H., Tighiouart, M., Lee, J. E. et al., Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int. J. Cancer 2008, 123, 1005-1014.
47. Amin, A. R., Khuri, F. R., Chen, Z. G., Shin, D. M., Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. Cancer Prev. Res. 2009, 2, 538-545.
48. Milligan, S. A., Burke, P., Coleman, D. T., Bigelow, R. L. et al., The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin. Cancer Res. 2009, 15, 4885-4894.
49. Shimizu, M., Deguchi, A., Hara, Y., Moriwaki, H. et al., EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. Biochem. Biophys. Res. Commun. 2005, 334, 947-953.
50. Shimizu, M., Shirakami, Y., Sakai, H., Tatebe, H. et al., EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Cancer Lett. 2008, 262, 10-18.
51. Adhami, V. M., Siddiqui, I. A., Ahmad, N., Gupta, S. et al., Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res. 2004, 64, 8715-8722.
52. Adhami, V. M., Siddiqui, I. A., Sarfaraz, S., Khwaja, S. I. et al., Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin. Cancer Res. 2009, 15, 1947-1953.
53. Yasuda, Y., Shimizu, M., Sakai, H., Iwasa, J. et al., (-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R. Chem. Biol. Interact. 2009, 182, 159-164.
54. Yoshida, H., Tateishi, R., Arakawa, Y., Sata, M. et al., Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004, 53, 425-430.
55. Shiratori, Y., Imazeki, F., Moriyama, M., Yano, M. et al., Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 2000, 132, 517-524.
56. Lee, Y. K., Bone, N. D., Strege, A. K., Shanafelt, T. D. et al., VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004, 104, 788-794.
57. Zhang, Q., Tang, X., Lu, Q., Zhang, Z. et al., Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol. Cancer Ther. 2006, 5, 1227-1238.
58. Jung, Y. D., Kim, M. S., Shin, B. A., Chay, K. O. et al., EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br. J. Cancer 2001, 84, 844-850.
59. Kataoka, H., Hamasuna, R., Itoh, H., Kitamura, N., Koono, M., Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res. 2000, 60, 6148-6159.
60. Takeuchi, H., Bilchik, A., Saha, S., Turner, R. et al., c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin. Cancer Res. 2003, 9, 1480-1488.
61. Larsen, C. A., Dashwood, R. H., Suppression of Met activation in human colon cancer cells treated with (-)-epigallocatechin-3-gallate: minor role of hydrogen peroxide. Biochem. Biophys. Res. Commun. 2009, 389, 527-530.
62. Larsen, C. A., Dashwood, R. H., (-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells. Arch. Biochem. Biophys 2010, 501, 52-57.
63. Sakata, R., Ueno, T., Nakamura, T., Sakamoto, M. et al., Green tea polyphenol epigallocatechin-3-gallate inhibits platelet-derived growth factor-induced proliferation of human hepatic stellate cell line LI90. J. Hepatol. 2004, 40, 52-59.
64. Kitano, K., Nam, K. Y., Kimura, S., Fujiki, H., Imanishi, Y., Sealing effects of (-)-epigallocatechin gallate on protein kinase C and protein phosphatase 2A. Biophys. Chem. 1997, 65, 157-164.
65. Kondo, T., Ohta, T., Igura, K., Hara, Y. et al., Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding. Cancer Lett. 2002, 180, 139-144.
66. Li, M., He, Z., Ermakova, S., Zheng, D. et al., Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 598-605.
67. Sah, J. F., Balasubramanian, S., Eckert, R. L., Rorke, E. A., Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J. Biol. Chem. 2004, 279, 12755-12762.
68. Peng, G., Wargovich, M. J., Dixon, D. A., Anti-proliferative effects of green tea polyphenol EGCG on Ha-Ras-induced transformation of intestinal epithelial cells. Cancer Lett. 2006, 238, 260-270.
69. Lievre, A., Bachet, J. B., Le Corre, D., Boige, V. et al., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66, 3992-3995.
70. Ju, J., Hong, J., Zhou, J. N., Pan, Z. et al., Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res. 2005, 65, 10623-10631.
71. Sukhthankar, M., Yamaguchi, K., Lee, S. H., McEntee, M. F. et al., A green tea component suppresses posttranslational expression of basic fibroblast growth factor in colorectal cancer. Gastroenterology 2008, 134, 1972-1980.
72. Powell, S. M., Zilz, N., Beazer-Barclay, Y., Bryan, T. M. et al., APC mutations occur early during colorectal tumorigenesis. Nature 1992, 359, 235-237.
73. Patra, S. K., Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim. Biophys. Acta 2008, 1785, 182-206.
74. Pike, L. J., Han, X., Gross, R. W., Epidermal growth factor receptors are localized to lipid rafts that contain a balance of inner and outer leaflet lipids: a shotgun lipidomics study. J. Biol. Chem. 2005, 280, 26796-26804.
75. Remacle-Bonnet, M., Garrouste, F., Baillat, G., Andre, F. et al., Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily. Am. J. Pathol. 2005, 167, 761-773.
76. Oshikawa, J., Urao, N., Kim, H. W., Kaplan, N. et al., Extracellular SOD-derived H2O2 promotes VEGF signaling in caveolae/lipid rafts and post-ischemic angiogenesis in mice. PLoS One 2010, 5, e10189.
77. Puri, C., Tosoni, D., Comai, R., Rabellino, A. et al., Relationships between EGFR signaling-competent and endocytosis-competent membrane microdomains. Mol. Biol. Cell 2005, 16, 2704-2718.
78. Fujimura, Y., Yamada, K., Tachibana, H., A lipid raft-associated 67kDa laminin receptor mediates suppressive effect of epigallocatechin-3-O-gallate on FcepsilonRI expression. Biochem. Biophys. Res. Commun. 2005, 336, 674-681.
79. Tachibana, H., Fujimura, Y., Yamada, K., Tea polyphenol epigallocatechin-3-gallate associates with plasma membrane lipid rafts: lipid rafts mediate anti-allergic action of the catechin. Biofactors 2004, 21, 383-385.
80. Sanjuan, X., Fernandez, P. L., Miquel, R., Munoz, J. et al., Overexpression of the 67-kD laminin receptor correlates with tumour progression in human colorectal carcinoma. J. Pathol. 1996, 179, 376-380.
81. Givant-Horwitz, V., Davidson, B., Reich, R., Laminin-induced signaling in tumor cells: the role of the M(r) 67, 000 laminin receptor. Cancer Res. 2004, 64, 3572-3579.
82. Givant-Horwitz, V., Davidson, B., Reich, R., Laminin-induced signaling in tumor cells. Cancer Lett. 2005, 223, 1-10.
83. Tachibana, H., Molecular basis for cancer chemoprevention by green tea polyphenol EGCG. Forum Nutr. 2009, 61, 156-169.
84. Adachi, S., Nagao, T., Ingolfsson, H. I., Maxfield, F. R. et al., The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res. 2007, 67, 6493-6501.
85. Adachi, S., Nagao, T., To, S., Joe, A. K. et al., (-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells. Carcinogenesis 2008, 29, 1986-1993.
86. Adachi, S., Shimizu, M., Shirakami, Y., Yamauchi, J. et al., (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells. Carcinogenesis 2009, 30, 1544-1552.
87. Masuda, M., Wakasaki, T., Toh, S., Shimizu, M., Adachi, S., Chemoprevention of head and neck cancer by green tea extract: EGCG-the role of EGFR signaling and "lipid raft". J. Oncol. 2011, 2011, 540148.
88. Fujiki, H., Suganuma, M., Imai, K., Nakachi, K., Green tea: cancer preventive beverage and/or drug. Cancer Lett. 2002, 188, 9-13.
89. Nakachi, K., Matsuyama, S., Miyake, S., Suganuma, M. et al., Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors 2000, 13, 49-54.
90. Gao, Y. T., McLaughlin, J. K., Blot, W. J., Ji, B. T. et al., Reduced risk of esophageal cancer associated with green tea consumption. J. Natl. Cancer Inst. 1994, 86, 855-858.
91. Zhang, M., Holman, C. D., Huang, J. P., Xie, X., Green tea and the prevention of breast cancer: a case-control study in Southeast China. Carcinogenesis 2007, 28, 1074-1078.
92. Li, N., Sun, Z., Han, C., Chen, J., The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proc. Soc. Exp. Biol. Med. 1999, 220, 218-224.
93. Bettuzzi, S., Brausi, M., Rizzi, F., Castagnetti, G. et al., Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006, 66, 1234-1240.
94. McLarty, J., Bigelow, R.L., Smith, M., Elmajian, D. et al., Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev. Res. 2009, 2, 673-682.
95. Stoner, G. D., Foodstuffs for preventing cancer: the preclinical and clinical development of berries. Cancer Prev. Res. 2009, 2, 187-194.
96. Luo, H., Tang, L., Tang, M., Billam, M. et al., Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine. Carcinogenesis 2006, 27, 262-268.
97. Tang, L., Tang, M., Xu, L., Luo, H. et al., Modulation of aflatoxin biomarkers in human blood and urine by green tea polyphenols intervention. Carcinogenesis 2008, 29, 411-417.
98. El-Serag, H. B., Rudolph, K. L., Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132, 2557-2576.
99. Muto, Y., Sato, S., Watanabe, A., Moriwaki, H. et al., Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol. Res. 2006, 35, 204-214.
100. Kao, Y. H., Chang, H. H., Lee, M. J., Chen, C. L., Tea, obesity, and diabetes. Mol. Nutr. Food Res. 2006, 50, 188-210.
101. Yang, C. S., Sang, S., Lambert, J. D., Lee, M. J., Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol. Nutr. Food Res. 2008, 52, S139-151.
102. Ermakova, S., Choi, B. Y., Choi, H. S., Kang, B. S. et al., The intermediate filament protein vimentin is a new target for epigallocatechin gallate. J. Biol. Chem. 2005, 280, 16882-16890.
103. He, Z., Tang, F., Ermakova, S., Li, M. et al., Fyn is a novel target of (-)-epigallocatechin gallate in the inhibition of JB6 Cl41 cell transformation. Mol. Carcinog. 2008, 47, 172-183.
104. Chow, H. H., Cai, Y., Hakim, I. A., Crowell, J. A. et al., Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin. Cancer Res. 2003, 9, 3312-3319.
105. Ahmad, N., Gupta, S., Mukhtar, H., Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch. Biochem. Biophys. 2000, 376, 338-346.
106. Weinstein, I. B., Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002, 297, 63-64.
107. Weinstein, I. B., Joe, A., Oncogene addiction. Cancer Res. 2008, 68, 3077-3080.